Pharsight

1. Oxaydo patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7510726	ZYLA	Methods and compositions for deterring abuse of opioid containing dosage forms	Nov, 2023 (4 months ago)
US8637540	ZYLA	Compositions for deterring abuse of opioid containing dosage forms	Nov, 2023 (4 months ago)
US8409616	ZYLA	Extended release opioid abuse deterrent compositions and methods of making same	Nov, 2023 (4 months ago)
US7981439	ZYLA	Methods and compositions for deterring abuse of drugs susceptible to abuse and dosage forms thereof	Nov, 2023 (4 months ago)
US9492443	ZYLA	Abuse deterrent compositions and methods of making same	May, 2024 (a month from now)
US7201920	ZYLA	Methods and compositions for deterring abuse of opioid containing dosage forms	Mar, 2025 (10 months from now)

Market Authorisation Date: 17 June, 2011

Treatment: NA

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
5 mg and 7.5 mg	07 Feb, 2012	1		16 Mar, 2025	Extinguished

Strength	Dosage	Availability
7.5MG	TABLET;ORAL	Discontinued
5MG	TABLET;ORAL	Discontinued

OXAYDO family patents

2. Oxycontin patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP06706682A	2017-12-19	G. L. Pharma GmbH	Revoked
EP11186168A	2016-10-11	James Poole Limited	Opposition rejected
EP10011792A	2015-10-28	Setna, Rohan P.	Granted and Under Opposition
EP10011792A	2015-10-28	Hoffmann Eitle	Granted and Under Opposition
EP10011792A	2015-10-27	James Poole Limited	Granted and Under Opposition
EP10011792A	2015-10-26	Acino Pharma AG	Granted and Under Opposition
EP05730345A	2011-12-09	Actavis group PTC ehf	Patent maintained as amended
EP05730345A	2011-12-08	Acino Pharma AG	Patent maintained as amended
EP05730345A	2011-12-05	Elend, Almut Susanne	Patent maintained as amended
EP2005006983W	2009-10-13	Sanofi-Aventis Deutschland GmbH	Patent maintained as amended
EP2005006983W	2009-10-13	Ypsomed AG	Patent maintained as amended
EP04763833A	2008-03-27	Purdue Pharma LP	Opposition rejected
EP04763834A	2007-12-14	Purdue Pharma LP	Opposition rejected

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US9492393	February, 2018	Terminated-Settled	Purdue Pharma L.P.	Kashiv Pharma, LLC
US9492392	February, 2018	Terminated-Settled	Purdue Pharma L.P.	Kashiv Pharma, LLC

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10696684	PURDUE PHARMA LP	Process for preparing oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone	Mar, 2025 (11 months from now)
US7674800	PURDUE PHARMA LP	Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone	Mar, 2025 (11 months from now)
US7683072	PURDUE PHARMA LP	Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone	Mar, 2025 (11 months from now)
US9073933	PURDUE PHARMA LP	Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone	Mar, 2025 (11 months from now)
US10407434	PURDUE PHARMA LP	Process for preparing oxycodone compositions	Mar, 2025 (11 months from now)
US9522919	PURDUE PHARMA LP	Oxycodone compositions	Mar, 2025 (11 months from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5508042	PURDUE PHARMA LP	Controlled release oxycodone compositions	Apr, 2013 (11 years ago)
US6488963	PURDUE PHARMA LP	Hot-melt extrudable pharmaceutical formulation	Jun, 2017 (6 years ago)
US8337888	PURDUE PHARMA LP	Pharmaceutical formulation containing gelling agent	Aug, 2022 (1 year, 8 months ago)
US9060976	PURDUE PHARMA LP	Pharmaceutical formulation containing gelling agent	Aug, 2022 (1 year, 8 months ago)
US10369109	PURDUE PHARMA LP	Abuse-proofed dosage form	Jun, 2023 (10 months ago)
US9675610	PURDUE PHARMA LP	Abuse-proofed dosage form	Jun, 2023 (10 months ago)
US10130591	PURDUE PHARMA LP	Abuse-proofed dosage form	Nov, 2023 (4 months ago)
US10675278	PURDUE PHARMA LP	Crush resistant delayed-release dosage forms	Nov, 2023 (4 months ago)
US8309060	PURDUE PHARMA LP	Abuse-proofed dosage form	Nov, 2023 (4 months ago)
US8114383	PURDUE PHARMA LP	Abuse-proofed dosage form	Oct, 2024 (5 months from now)
US7674799	PURDUE PHARMA LP	Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone	Mar, 2025 (11 months from now)
US7683072	PURDUE PHARMA LP	Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone	Mar, 2025 (11 months from now)
US7674800	PURDUE PHARMA LP	Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone	Mar, 2025 (11 months from now)
US7776314	PURDUE PHARMA LP	Abuse-proofed dosage system	Apr, 2025 (11 months from now)
US9492393	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (3 years from now)
US9770416	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (3 years from now)
US9492392	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (3 years from now)
US11304909	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (3 years from now)
US8894988	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (3 years from now)
US11304908	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (3 years from now)
US9775808	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (3 years from now)
US9492389	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (3 years from now)
US9492391	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (3 years from now)
US9763933	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (3 years from now)
US8808741	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (3 years from now)
US8894987	PURDUE PHARMA LP	Tamper resistant dosage forms	Mar, 2030 (5 years from now)

Market Authorisation Date: 12 December, 1995

Treatment: Management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time; Management of pain severe enough to require daily, around-the-clock, long ...

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
30MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
15MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
160MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
40MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
20MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
10MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
80MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
60MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

OXYCONTIN family patents

3. Roxybond patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7955619	PROTEGA PHARMS	Abuse resistant drugs, method of use and method of making	Aug, 2028 (4 years from now)
US10314788	PROTEGA PHARMS	Pharmaceutical compositions configured to deter dosage form splitting	Aug, 2028 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Apr 20, 2020

Market Authorisation Date: 20 April, 2017